Conclusively, these findings are the first report demonstrating the potential of Calebin A as an anti-proinflammatory and anti-tumor active compound in the management of TNF-β-stimulated colorectal cancer cell malignity through the targeting and inhibition of activation, nuclear translocation and DNA-binding of p65-NF-κB (Figure 7). The gene discussed is NFKB1; the disease is neoplasm.